November 21, 2024SHILAP Revista de lepidopterología51 citationsOpen Access

SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)

PPPasquale PaolissoStructural Heart Disease MBMarta BelmonteInterventional Cardiology EGEmanuele GallinoroInterventional Cardiology

Structured PICO

Does the use of SGLT2 inhibitors improve cardiac remodeling and reduce MACE in diabetic patients with severe aortic stenosis, LVEF < 50%, and EVCD undergoing TAVI?

Population

Diabetic patients with severe aortic stenosis (AS), LVEF < 50%, and extra-valvular cardiac damage (EVCD) undergoing transcatheter aortic valve implantation (TAVI)

Intervention

SGLT2 inhibitors

Outcome

Cardiac remodeling and risk of major adverse cardiovascular events (MACE) at 2-year follow-upcomposite

SGLT2 inhibitors may improve cardiac remodeling and reduce adverse cardiovascular events in diabetic patients with severe aortic stenosis and reduced LVEF undergoing TAVI.

Abstract

In diabetic patients with severe AS, LVEF < 50%, and EVCD undergoing TAVI, the use of SGLT2i was associated with a more favorable cardiac remodeling and a reduced risk of MACE at 2-year follow-up.

Ask AI

Helpful

Bookmark

View Full Paper